Search

Your search keyword '"Verzenio (Medication)"' showing total 50 results
Start Over Descriptor "Verzenio (Medication)" Journal plus company updates
50 results on '"Verzenio (Medication)"'

1. Lilly reports full Q4 2024 financial results and provides 2025 guidance

Subjects
Boehringer Ingelheim GmbH -- Company sales and earnings, Eli Lilly and Co. -- Company sales and earnings, Jardiance (Medication), Trulicity (Medication), Verzenio (Medication), Mounjaro (Medication), Humalog (Medication), Zepbound (Medication), Diseases, Company sales and earnings, Company earnings/profit, Chronic diseases, Insulin lispro, Semaglutide
Abstract

INDIANAPOLIS: Eli Lilly and Company has issued the following news release: Eli Lilly and Company (NYSE: LLY) announced its financial results for the fourth quarter of 2024 and detailed 2025 [...]

Published
2025

2. Lilly's Imlunestrant, an Oral SERD, Significantly Improved Progression-Free Survival as Monotherapy and in Combination with Verzenio(r) (abemaciclib) in Patients with ER+, HER2- Advanced Breast Cancer

Subjects
Eli Lilly and Co., Breast cancer -- Care and treatment -- Patient outcomes, Fulvestrant, General interest, News, opinion and commentary, Verzenio (Medication)
Abstract

INDIANAPOLIS: Eli Lilly and Company has issued the following press release: - Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 EMBER-3 study of imlunestrant, an [...]

Published
2024

3. Lilly Reports Q2 2024 Financial Results, Raises Full-Year Revenue Guidance by $3 Billion

Subjects
Eli Lilly and Co. -- Company sales and earnings, Company earnings/profit, General interest, News, opinion and commentary, Verzenio (Medication), Mounjaro (Medication), Zepbound (Medication)
Abstract

INDIANAPOLIS: Eli Lilly and Company has issued the following news release: Eli Lilly and Company (NYSE: LLY) today announced its financial results for the second quarter of 2024. 'Mounjaro, Zepbound [...]

Published
2024

4. Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO(r)) in Women with ER+|HER2- Breast Cancer

Subjects
Eli Lilly and Co., Clinical trials, Breast cancer, Pharmaceutical industry, General interest, News, opinion and commentary, Verzenio (Medication)
Abstract

SEATTLE: Atossa Therapeutics, Inc. has issued the following news release: Atossa Therapeutics, Inc. (Nasdaq: ATOS) ('Atossa' or the 'Company') today announced protocol changes in the previously initiated study to evaluate [...]

Published
2024

5. Lilly Announces Details of Presentations at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Subjects
Eli Lilly and Co. -- Conferences, meetings and seminars, Trade and professional associations -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, General interest, News, opinion and commentary, Verzenio (Medication), Retevmo (Medication)
Abstract

INDIANAPOLIS: Eli Lilly and Company has issued the following news release: Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Verzenio(r) (abemaciclib; a CDK4/6 inhibitor), Retevmo(r) [...]

Published
2024

6. Lilly Reports Strong Fourth-Quarter 2023 Financial Results and Provides 2024 Guidance

Subjects
Eli Lilly and Co. -- Company sales and earnings, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, General interest, News, opinion and commentary, Jardiance (Medication), Trulicity (Medication), Verzenio (Medication), Mounjaro (Medication), Taltz (Medication), Humalog (Medication)
Abstract

INDIANAPOLIS: Eli Lilly and Company has issued the following news release: Eli Lilly and Company (NYSE: LLY) today announced its financial results for the fourth quarter of 2023. '2023 was [...]

Published
2024

7. Lilly to Present Final Overall Survival Analysis from the MONARCH 3 Study of Verzenio(r) (abemaciclib) and Additional Results from Its Breast Cancer Portfolio at the 2023 San Antonio Breast Cancer Symposium

Subjects
Eli Lilly and Co., Oncology, Experimental, Postmenopausal women -- Patient outcomes, Metastasis -- Patient outcomes, Cancer -- Research, Breast cancer -- Patient outcomes, General interest, News, opinion and commentary, Verzenio (Medication)
Abstract

INDIANAPOLIS: Eli Lilly and Company has issued the following news release: Eli Lilly and Company (NYSE: LLY) announced results from the MONARCH 3 clinical trial, which will be presented in [...]

Published
2023

8. Lilly Reports Third-Quarter 2023 Financial Results, Highlights Strong Sales Growth and Business Development Activity

Subjects
United States. Food and Drug Administration, Eli Lilly and Co., Pharmaceutical industry, General interest, News, opinion and commentary, Jardiance (Medication), Trulicity (Medication), Verzenio (Medication), Mounjaro (Medication), Taltz (Medication)
Abstract

INDIANAPOLIS: Eli Lilly and Company has issued the following news release: Eli Lilly and Company (NYSE: LLY) today announced its financial results for the third quarter of 2023. 'Lilly had [...]

Published
2023

9. Lilly Announces Details of Presentations at ESMO Congress 2023

Subjects
Eli Lilly and Co., Oncology, Experimental, Antineoplastic agents, Cancer -- Research, Pharmaceutical industry, Antimitotic agents, General interest, News, opinion and commentary, Verzenio (Medication), Retevmo (Medication)
Abstract

INDIANAPOLIS: Eli Lilly and Company has issued the following news release: Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Verzenio(r) (abemaciclib; a CDK4/6 inhibitor), Retevmo(r) [...]

Published
2023

10. On the Road to Halving Cancer: The 2023 Biotech Advancements Igniting Hope

Subjects
Oncolytics Biotech Inc. -- Planning, Eli Lilly and Co. -- Planning, Biotechnology, Biotechnology industry -- Planning, Cancer -- Development and progression, Pharmaceutical industry -- Planning, Company business planning, General interest, News, opinion and commentary, Verzenio (Medication)
Abstract

VANCOUVER, British Columbia: USA News Group has issued the following news release: USA News Group - Earlier this year, the US White House requested over $2.8 billion in funding from [...]

Published
2023

11. Novartis medication reduces early-stage breast cancer recurrence by 25%

Subjects
Novartis AG, Eli Lilly and Co., Diseases -- Relapse, Cancer -- Prevention, Breast cancer -- Drug therapy, Pharmaceutical industry, General interest, News, opinion and commentary, Verzenio (Medication), Kisqali (Medication)
Abstract

Novartis breast cancer drug Kisqali cut the risk of recurrence by 25% in early-stage breast cancer, positioning the Swiss drugmaker to win new patients and challenge strong rival Eli Lilly. [...]

Published
2023

12. Lilly Reports Fourth-Quarter 2022 Financial Results, Core Business Growth and Pipeline Advancements Support Strong Long-Term Outlook

Subjects
United States. Food and Drug Administration, Eli Lilly and Co. -- Company sales and earnings, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, General interest, News, opinion and commentary, Olumiant (Medication), Jardiance (Medication), Trulicity (Medication), Verzenio (Medication), Mounjaro (Medication), Humalog (Medication)
Abstract

INDIANAPOLIS: Eli Lilly and Company has issued the following news release: Eli Lilly and Company (NYSE: LLY) today announced its financial results for the fourth quarter of 2022. '2023 is [...]

Published
2023

13. Lilly Announces Details of Presentations at 2022 San Antonio Breast Cancer Symposium

Subjects
Eli Lilly and Co. -- Conferences, meetings and seminars, Oncology, Experimental -- Conferences, meetings and seminars, Conferences and conventions -- Conferences, meetings and seminars, Estrogen -- Conferences, meetings and seminars, Breast cancer -- Conferences, meetings and seminars, Cancer -- Research, Fulvestrant -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, General interest, News, opinion and commentary, Verzenio (Medication)
Abstract

United States: Eli Lilly and Company has issued the following news release: Eli Lilly and Company (NYSE: LLY) today announced that study investigators will present data from its breast cancer [...]

Published
2022

14. Lilly Announces Details of Presentations at ESMO Congress 2022

Subjects
Eli Lilly and Co., Fulvestrant, Pharmaceutical industry, General interest, News, opinion and commentary, Verzenio (Medication), Retevmo (Medication)
Abstract

INDIANAPOLIS: Eli Lilly and Company has issued the following news release: Eli Lilly and Company ( NYSE: LLY) today announced that data from studies of Verzenio(r) (abemaciclib) and Retevmo(r) (selpercatinib) [...]

Published
2022

15. Lilly Reports Second-Quarter Financial Results, Highlights Momentum of New Medicines and Pipeline Advancements

Subjects
Eli Lilly and Co. -- Company sales and earnings, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, General interest, News, opinion and commentary, Olumiant (Medication), Jardiance (Medication), Verzenio (Medication), Mounjaro (Medication), Humalog (Medication)
Abstract

INDIANAPOLIS: Eli Lilly and Company has issued the following news release: Eli Lilly and Company (NYSE: LLY) today announced its financial results for the second quarter of 2022. 'We had [...]

Published
2022

16. Lilly Announces Details of Presentations at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Subjects
Eli Lilly and Co. -- Conferences, meetings and seminars, Oncology, Experimental -- Conferences, meetings and seminars, Trade and professional associations -- Conferences, meetings and seminars, Estrogen -- Conferences, meetings and seminars, Cancer -- Research, Pharmaceutical industry -- Conferences, meetings and seminars, General interest, News, opinion and commentary, Verzenio (Medication), Retevmo (Medication)
Abstract

INDIANAPOLIS: Eli Lilly and Company has issued the following news release: Eli Lilly and Company (NYSE: LLY) today announced that data from its oncology portfolio will be presented at the [...]

Published
2022

17. Lilly Reports Solid Fourth-Quarter and Full-Year 2021 Financial Results, Recent Late-Stage Pipeline Successes Set Up Next Wave of Innovative Medicines for Patients

Subjects
United States. Food and Drug Administration, Boehringer Ingelheim GmbH -- Company sales and earnings, Eli Lilly and Co. -- Company sales and earnings, Pipe lines, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, General interest, News, opinion and commentary, Olumiant (Medication), Jardiance (Medication), Basaglar (Medication), Trulicity (Medication), Forteo (Medication), Verzenio (Medication), Cyramza (Medication), Retevmo (Medication), Taltz (Medication), Humalog (Medication), Emgality (Medication)
Abstract

INDIANAPOLIS: Eli Lilly and Company has issued the following news release: Eli Lilly and Company (NYSE: LLY) announced financial results for the fourth quarter and full year of 2021 today. [...]

Published
2022

18. Lilly Reports Robust Third-Quarter 2021 Financial Results as Pipeline Success Strengthens Future Growth Potential

Subjects
United States. Food and Drug Administration, Eli Lilly and Co. -- Company sales and earnings, Pipe lines, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, General interest, News, opinion and commentary, Olumiant (Medication), Jardiance (Medication), Trulicity (Medication), Verzenio (Medication), Retevmo (Medication)
Abstract

United States: Eli Lilly and Company has issued the following news release: Eli Lilly and Company (NYSE: LLY) announced financial results for the third quarter of 2021 today. 'Lilly demonstrated [...]

Published
2021

20. Lilly to Present New Data from Oncology Portfolio at ESMO Congress

Subjects
Eli Lilly and Co., Fulvestrant, Pharmaceutical industry, General interest, News, opinion and commentary, Verzenio (Medication), Cyramza (Medication), Retevmo (Medication)
Abstract

INDIANAPOLIS: Eli Lilly and Company has issued the following news release: New data from various studies of Eli Lilly and Company's (NYSE: LLY) Verzenio(r) (abemaciclib), Retevmo(r) (selpercatinib) and CYRAMZA(r) (ramucirumab) [...]

Published
2021

21. Lilly Announces Details of Presentations at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

Subjects
Eli Lilly and Co. -- Conferences, meetings and seminars, Cancer -- Adjuvant treatment, Trade and professional associations -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Estrogen -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, General interest, News, opinion and commentary, Verzenio (Medication), Retevmo (Medication)
Abstract

INDIANAPOLIS: Eli Lilly and Company has issued the following news release: New data from across Eli Lilly and Company's (NYSE: LLY) oncology portfolio will be presented at the 2021 American [...]

Published
2021

22. Lilly Delivers First-Quarter 2021 Financial Results, Adjusts 2021 Financial Guidance

Subjects
United States. Food and Drug Administration, Rigel Pharmaceuticals Inc. -- Company sales and earnings -- Company forecasts, Eli Lilly and Co. -- Company sales and earnings -- Company forecasts, Biotechnology industry -- Company sales and earnings, Pharmaceutical industry -- Company sales and earnings, Company business forecast/projection, Company earnings/profit, General interest, News, opinion and commentary, Olumiant (Medication), Jardiance (Medication), Basaglar (Medication), Trulicity (Medication), Forteo (Medication), Verzenio (Medication), Cyramza (Medication), Retevmo (Medication), Taltz (Medication), Humalog (Medication), Emgality (Medication)
Abstract

Indianapolis: Eli Lilly and Company has issued the following press release: Eli Lilly and Company (NYSE: LLY) today announced financial results for the first quarter of 2021. $ in millions, [...]

Published
2021

23. Lilly Reports Strong Fourth-Quarter and Full-Year 2020 Financial Results

Subjects
Eli Lilly and Co. -- Company sales and earnings, Therapeutics Inc. -- Company sales and earnings, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, General interest, News, opinion and commentary, Olumiant (Medication), Jardiance (Medication), Basaglar (Medication), Trulicity (Medication), Forteo (Medication), Verzenio (Medication), Baqsimi (Medication), Cyramza (Medication), Retevmo (Medication), Taltz (Medication), Humalog (Medication), Emgality (Medication)
Abstract

United States: Eli Lilly and Company has issued the following news release: Eli Lilly and Company (NYSE: LLY) today announced financial results for the fourth quarter and full year of [...]

Published
2021

24. Lilly Presents Positive Primary Outcome Data from monarchE that Builds on Previous Definitive Analysis for Verzenio

Subjects
Eli Lilly and Co., Pharmaceutical industry, Abemaciclib, Adjuvant chemotherapy, General interest, News, opinion and commentary, Verzenio (Medication)
Abstract

Indianapolis: Eli Lilly and Company has issued the following press release: Eli Lilly and Company (NYSE: LLY) today announced additional data from a pre-planned primary outcome analysis from the Phase [...]

Published
2020

25. Lilly Presents Positive Primary Outcome Data from monarchE that Builds on Previous Definitive Analysis for Verzenio(r)

Subjects
Eli Lilly and Co., Pharmaceutical industry, Abemaciclib, Adjuvant chemotherapy, General interest, News, opinion and commentary, Verzenio (Medication)
Abstract

United States: Eli Lilly and Company has issued the following news release: Eli Lilly and Company (NYSE: LLY) today announced additional data from a pre-planned primary outcome analysis from the [...]

Published
2020

26. Lilly Reports Third Quarter Financial Results, Updates Guidance

Subjects
United States. Food and Drug Administration, Eli Lilly and Co. -- Company sales and earnings, Company earnings/profit, General interest, News, opinion and commentary, Jardiance (Medication), Basaglar (Medication), Trulicity (Medication), Forteo (Medication), Verzenio (Medication), Cyramza (Medication), Taltz (Medication)
Abstract

Indianapolis: Eli Lilly and Company has issued the following press release: Eli Lilly and Company (NYSE: LLY) today announced financial results for the third quarter of 2020. $ in millions, [...]

Published
2020

27. Lilly Reports Third-Quarter Financial Results, Updates Guidance

Subjects
United States. Food and Drug Administration, Eli Lilly and Co. -- Company sales and earnings, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, General interest, News, opinion and commentary, Olumiant (Medication), Jardiance (Medication), Basaglar (Medication), Trulicity (Medication), Forteo (Medication), Verzenio (Medication), Baqsimi (Medication), Cyramza (Medication), Retevmo (Medication), Taltz (Medication), Emgality (Medication)
Abstract

Indianapolis: Eli Lilly and Company has issued the following press release: Eli Lilly and Company (NYSE: LLY) today announced financial results for the third quarter of 2020. $ in millions, [...]

Published
2020

28. Verzenio Significantly Reduced the Risk of Cancer Recurrence by 25% for People with HR+, HER2- High Risk Early Breast Cancer

Subjects
Eli Lilly and Co., Cancer recurrence -- Risk factors, Cancer prevention, Pharmaceutical industry, Abemaciclib, Breast cancer -- Risk factors, Adjuvant chemotherapy, General interest, News, opinion and commentary, Verzenio (Medication)
Abstract

Indianapolis: Eli Lilly and Company has issued the following press release: Eli Lilly and Company (NYSE: LLY) today announced Verzenio(r) (abemaciclib) in combination with standard adjuvant endocrine therapy (ET) significantly [...]

Published
2020

29. Verzenio(r) Significantly Reduced the Risk of Cancer Recurrence by 25% for People with HR+, HER2- High Risk Early Breast Cancer

Subjects
Eli Lilly and Co., Cancer recurrence -- Risk factors, Cancer prevention, Pharmaceutical industry, Abemaciclib, Breast cancer -- Risk factors, Adjuvant chemotherapy, General interest, News, opinion and commentary, Verzenio (Medication)
Abstract

United States: Eli Lilly and Company has issued the following news release: Eli Lilly and Company (NYSE: LLY) today announced Verzenio(r) (abemaciclib) in combination with standard adjuvant endocrine therapy (ET) [...]

Published
2020

30. Lilly Reports Second-Quarter Financial Results, Raises EPS Guidance

Subjects
United States. Food and Drug Administration, Eli Lilly and Co. -- Company sales and earnings -- Forecasts and trends, Pharmaceutical industry -- Forecasts and trends -- Company sales and earnings, Market trend/market analysis, Company earnings/profit, General interest, News, opinion and commentary, Olumiant (Medication), Jardiance (Medication), Basaglar (Medication), Trulicity (Medication), Forteo (Medication), Verzenio (Medication), Baqsimi (Medication), Cyramza (Medication), Retevmo (Medication), Taltz (Medication), Emgality (Medication)
Abstract

INDIANAPOLIS: Eli Lilly and Company has issued the following press release: Certain financial information for 2020 and 2019 is presented on both a reported and a non-GAAP basis. Some numbers [...]

Published
2020

31. Lilly Reports Strong First-Quarter Financial Results, Adjusts EPS Guidance

Subjects
United States. Food and Drug Administration, Eli Lilly and Co. -- Company sales and earnings -- Forecasts and trends, Pharmaceutical industry -- Forecasts and trends -- Company sales and earnings, Finance, Market trend/market analysis, Company earnings/profit, General interest, News, opinion and commentary, Olumiant (Medication), Jardiance (Medication), Basaglar (Medication), Trulicity (Medication), Verzenio (Medication), Cyramza (Medication), Taltz (Medication), Humalog (Medication), Emgality (Medication), Lartruvo (Medication)
Abstract

INDIANAPOLIS: Eli Lilly and Company has issued the following news release: Eli Lilly and Company (NYSE: LLY) today announced financial results for the first quarter of 2020. $ in millions, [...]

Published
2020

32. Verzenio: 2019 Drug Insight Report

Subjects
Drugs, Clinical trials, Partnerships, Patents, General interest, News, opinion and commentary, Verzenio (Medication)
Abstract

DUBLIN: Research and Markets has issued the following press release: The 'Verzenio - Drug Insight, 2019' report has been added to ResearchAndMarkets.com's offering. This report provides comprehensive information of the [...]

Published
2019

33. Verzenio (abemaciclib) Significantly Extends Life by a Median of 9.4 Months for Women with HR+, HER2- Advanced Breast Cancer in MONARCH 2 Study

Subjects
Cancer research, Postmenopausal women, Fulvestrant, Abemaciclib, Breast cancer, Epidermal growth factors, Hormones, Clinical trials, Cancer metastasis, General interest, News, opinion and commentary, Verzenio (Medication)
Abstract

Toronto: Eli Lilly Canada has issued the following news release: Eli Lilly and Company (NYSE: LLY) announced that Verzenio (abemaciclib) in combination with fulvestrant significantly extended life by a median [...]

Published
2019

34. Verzenio(r) (abemaciclib) Significantly Extends Life by a Median of 9.4 Months for Women with HR+, HER2- Advanced Breast Cancer in MONARCH 2 Study

Subjects
Eli Lilly and Co., Cancer research, Postmenopausal women, Fulvestrant, Pharmaceutical industry, Abemaciclib, Breast cancer, Epidermal growth factors, Hormones, Clinical trials, Cancer metastasis, General interest, News, opinion and commentary, Verzenio (Medication)
Abstract

INDIANAPOLIS: Eli Lilly and Company has issued the following press release: Eli Lilly and Company (NYSE: LLY) today announced Verzenio(r) (abemaciclib) in combination with fulvestrant significantly extended life by a [...]

Published
2019

35. Lilly Oncology to Present Robust Data across Its Growing Portfolio at ESMO 2019

Subjects
Eli Lilly and Co., Ramucirumab, Carboplatin, Fulvestrant, Pembrolizumab, Pharmaceutical industry, Abemaciclib, Pemetrexed, Cancer, General interest, News, opinion and commentary, Verzenio (Medication)
Abstract

Dublin: Eli Lilly has issued the following press release: Eli Lilly and Company (NYSE: LLY) today announced data from a number of studies across the company's oncology product portfolio will [...]

Published
2019

36. Lilly's Verzenio(r) (abemaciclib) Significantly Extended Life in Women with HR+, HER2- Advanced Breast Cancer in MONARCH 2

Subjects
Eli Lilly and Co., Postmenopausal women -- Care and treatment, Fulvestrant, Pharmaceutical industry, Abemaciclib, Breast cancer -- Care and treatment, Epidermal growth factors, Hormones, Clinical trials, Cancer metastasis, Women, General interest, News, opinion and commentary, Verzenio (Medication)
Abstract

INDIANAPOLIS: Eli Lilly and Company has issued the following news release: Eli Lilly and Company (NYSE: LLY) today announced that Verzenio (abemaciclib) demonstrated a statistically significant improvement in overall survival [...]

Published
2019

37. Lilly Reports Second-Quarter 2019 Financial Results, Raises 2019 EPS Guidance

Subjects
United States. Food and Drug Administration, Eli Lilly and Co. -- Company sales and earnings, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, General interest, News, opinion and commentary, Jardiance (Medication), Basaglar (Medication), Trulicity (Medication), Verzenio (Medication), Cialis (Medication), Taltz (Medication), Emgality (Medication)
Abstract

Indianapolis: Eli Lilly and Company has issued the following press release: Eli Lilly and Company (NYSE: LLY) today announced financial results for the second quarter of 2019. $ in millions, [...]

Published
2019

38. Lilly's Verzenio (abemaciclib) Significantly Extended Life in Women with HR+, HER2- Advanced Breast Cancer in MONARCH 2

Subjects
Eli Lilly and Co., Postmenopausal women -- Care and treatment, Fulvestrant, Pharmaceutical industry, Abemaciclib, Breast cancer -- Care and treatment, Epidermal growth factors, Hormones, Clinical trials, Cancer metastasis, Women, General interest, News, opinion and commentary, Verzenio (Medication)
Abstract

Indianapolis: Eli Lilly and Company has issued the following press release: Eli Lilly and Company (NYSE: LLY) today announced that Verzenio (abemaciclib) demonstrated a statistically significant improvement in overall survival [...]

Published
2019

39. Lilly Reports Strong First-Quarter 2017 Results, Raised EPS Guidance

Subjects
Eli Lilly and Co. -- Company sales and earnings, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, General interest, News, opinion and commentary, Jardiance (Medication), Basaglar (Medication), Trulicity (Medication), Verzenio (Medication), Cyramza (Medication), Taltz (Medication)
Abstract

Amsterdam: LILLY AND CO has issued the following news release: - First-quarter 2018 revenue increased 9 percent, driven primarily by the increased demand for new pharmaceutical products, while operating expenses [...]

Published
2018

40. Lilly Receives Additional FDA Approval for Verzenio (abemaciclib), as Initial Treatment for Advanced Breast Cance

Subjects
United States. Food and Drug Administration, Eli Lilly and Co., Postmenopausal women -- Drug therapy, Pharmaceutical industry, Drug approval, Cancer metastasis -- Drug therapy, General interest, News, opinion and commentary, Verzenio (Medication)
Abstract

INDIANAPOLIS: Eli Lilly and Company has issued the following press release: Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved VerzenioTM [...]

Published
2018

41. Lilly Receives Additional FDA Approval for Verzenio (abemaciclib), as Initial Treatment for Advanced Breast Cancer

Subjects
United States. Food and Drug Administration, Eli Lilly and Co., Cancer treatment, Postmenopausal women -- Drug therapy, Pharmaceutical industry, Drug approval, Breast cancer -- Drug therapy, Cancer metastasis -- Drug therapy, General interest, News, opinion and commentary, Verzenio (Medication)
Abstract

Indianapolis: Eli Lilly and Company has issued the following press release: Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved VerzenioTM [...]

Published
2018

42. Lilly Reports Strong Fourth-Quarter and Full-Year 2017 Revenue Growth, Increases 2018 EPS Guidance

Subjects
Novartis AG -- Company sales and earnings -- Taxation, AstraZeneca PLC -- Company sales and earnings -- Taxation, Eli Lilly and Co. -- Company sales and earnings -- Taxation, Pharmaceutical industry -- Company sales and earnings -- Taxation, Company earnings/profit, General interest, News, opinion and commentary, Jardiance (Medication), Basaglar (Medication), Trulicity (Medication), Forteo (Medication), Verzenio (Medication), Cialis (Medication), Cyramza (Medication), Taltz (Medication), Humalog (Medication), Lartruvo (Medication)
Abstract

Clinton, IN: Eli Lilly has issued the following news release: Fourth-quarter 2017 revenue increased 7 percent, driven primarily by volume growth from new pharmaceutical products, while operating expenses remained flat. [...]

Published
2018

43. Lilly Announces 2018 Financial Guidance and Enhances Outlook Through 2020

Subjects
Eli Lilly and Co., Rheumatoid factor, Pharmaceutical industry, Antiarthritic agents, General interest, News, opinion and commentary, Jardiance (Medication), Basaglar (Medication), Trulicity (Medication), Verzenio (Medication), Cyramza (Medication), Taltz (Medication), Lartruvo (Medication)
Abstract

Amsterdam: LILLY AND CO has issued the following news release: -- 2018 revenue is expected to be between $23.0 billion and $23.5 billion, representing low-single-digit growth driven by volume from [...]

Published
2017

44. Lilly Reports Third-Quarter Results, Announces Strategic Review of Elanco Animal Health

Subjects
Novartis AG, Eli Lilly and Co., Pharmaceutical industry, General interest, News, opinion and commentary, Jardiance (Medication), Posilac (Growth regulator), Basaglar (Medication), Trulicity (Medication), Forteo (Medication), Verzenio (Medication), Cialis (Medication), Cyramza (Medication), Portrazza (Medication), Taltz (Medication), Humalog (Medication), Lartruvo (Medication)
Abstract

Basingstoke, UK: Eli Lilly has issued the following press release: Third-quarter 2017 revenue increased 9 percent, driven primarily by volume growth from new pharmaceutical products. Third-quarter 2017 earnings per share [...]

Published
2017

45. Lilly Reports Third-Quarter Results, Announces Strategic Review of Elanco Animal Health

Subjects
Eli Lilly and Co., Pharmaceutical industry, General interest, News, opinion and commentary, Jardiance (Medication), Basaglar (Medication), Trulicity (Medication), Verzenio (Medication), Cialis (Medication), Cyramza (Medication), Taltz (Medication), Humalog (Medication), Lartruvo (Medication)
Abstract

Indianapolis : Eli Lilly has issued the following press release: Third-quarter 2017 revenue increased 9 percent, driven primarily by volume growth from new pharmaceutical products. Third-quarter 2017 earnings per share [...]

Published
2017

46. Lilly Reports Third-Quarter Results, Announces Strategic Review of Elanco Animal Health

Subjects
Eli Lilly and Co., Pharmaceutical industry, General interest, News, opinion and commentary, Jardiance (Medication), Verzenio (Medication)
Abstract

Amsterdam: LILLY AND CO has issued the following news release: - Third-quarter 2017 revenue increased 9 percent, driven primarily by volume growth from new pharmaceutical products. Third-quarter 2017 earnings per [...]

Published
2017

47. FDA Grants Priority Review for Potential New Indication for Lilly's Verzenio (abemaciclib) as Initial Treatment of Advanced Breast Cancer

Subjects
United States. Food and Drug Administration, Eli Lilly and Co., Cancer treatment, Pharmaceutical industry, Breast cancer, Cancer metastasis, General interest, News, opinion and commentary, Verzenio (Medication)
Abstract

Basingstoke, UK: Eli Lilly has issued the following press release: Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review [...]

Published
2017

48. VERZENIO (abemaciclib) Approved for Treatment of Metastatic Breast Cancer, Available for Order at Biologics, Inc

Subjects
United States. Food and Drug Administration, McKesson Corp., Eli Lilly and Co., Cancer treatment, Pharmaceutical industry, Drug approval, Breast cancer, Cancer metastasis, General interest, News, opinion and commentary, Verzenio (Medication)
Abstract

California : McKesson Corporation has issued the following Press Release : McKesson Specialty Health oncology pharmacy services company, has been selected by Eli Lilly and Company to be in the [...]

Published
2017

49. Lilly Receives U.S. FDA Approval of Verzenio (abemaciclib)

Subjects
United States. Food and Drug Administration, Eli Lilly and Co., Chemotherapy, Pharmaceutical industry, Drug approval, Cancer metastasis, General interest, News, opinion and commentary, Verzenio (Medication)
Abstract

Cambridge, MA: Eli Lilly has issued the following news release: Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved Verzenio (abemaciclib) in [...]

Published
2017

50. Lilly MONARCH 3 Study Published in Journal of Clinical Oncology Demonstrates Benefit of Verzenio (abemaciclib) Plus NSAI in Advanced Breast Cancer

Subjects
Eli Lilly and Co., Pharmaceutical industry, Breast cancer, General interest, News, opinion and commentary, European Society for Medical Oncology, Verzenio (Medication)
Abstract

Cambridge, MA: Eli Lilly has issued the following news release: Eli Lilly and Company (NYSE: LLY) today announced that interim results from the double-blind, placebo-controlled Phase 3 MONARCH 3 study [...]

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results